Pay in 4 interest-free payments of $7.31 Learn more
Ships within 48 hours · Estimated delivery Nov 9 - Nov 14
Unimolecular dual GLP-1R/GCGR agonist balanced receptor profile distinct from GLP-1 mono-agonists and GLP-1/GIP dual agonists Oxyntomodulin-based backbone naturally derived structural scaffold with endogenous GLP-1R/GCGR dual activity Ki 17.7 nM at human GCGR and 28.6 nM at human GLP-1R reference binding data from MedChemExpress Long-acting fatty acid lipidation albumin binding for extended receptor engagement in experimental models First dual GLP-1R/GCGR agonist to complete Phase 3 and receive regulatory acceptance GLORY program (China) Studied alongside GLP-1 mono-agonists (Semaglutide) and triple agonists (Retatrutide) for comparative receptor pathway biology Lyophilized format ensures stability and reproducibility across experimental runs Batch and lot identifiers on all labeling for full laboratory documentation compliance Research Background Mazdutide was originally developed by Eli Lilly as LY3305677 and subsequently licensed to Innovent Biologics for development as IBI362
If budget is a factor and anti-inflammation is not a priority, Glow offers excellent value for money
Always consult with your prescriber to determine the best treatment plan
Learn about dosing, side effects, and whether youre a good candidate
